Abstract
Plant proteins have been drawing increasing attention owing to their safety, abundance and relatively low cost in comparison with animal proteins. The development of plant protein-based delivery vehicles may lead to the provision of novel pharmaceutical products to patients. Zein is a class of alcohol-soluble prolamine proteins present in maize endosperm that was approved as a generally recognised as safe excipient in 1985 by the US FDA for use in pharmaceutical film coatings. Over the past few decades, numerous studies have been carried out to illustrate zein’s potential for novel applications in the biomedical field. This paper reviews the present status of zein-based nanofibres, with emphasis on their fabrication and biomedical applications, particularly for drug delivery. Their benefits and limitations are also discussed to provide further insight into zein’s potential as a promising biomaterial.
Keywords: Biocompatibility, biomedical application, biopolymer, immunogenicity, zein.
Current Pharmaceutical Design
Title:Zein-Based Nanofibres for Drug Delivery: Classes and Current Applications
Volume: 21 Issue: 22
Author(s): Yong Zhang, Lili Cui, Yan Chen, Heng Zhang, Jian Zhong, Yanan Sun, Nianqiu Shi, Chunlei Li and Wei Kong
Affiliation:
Keywords: Biocompatibility, biomedical application, biopolymer, immunogenicity, zein.
Abstract: Plant proteins have been drawing increasing attention owing to their safety, abundance and relatively low cost in comparison with animal proteins. The development of plant protein-based delivery vehicles may lead to the provision of novel pharmaceutical products to patients. Zein is a class of alcohol-soluble prolamine proteins present in maize endosperm that was approved as a generally recognised as safe excipient in 1985 by the US FDA for use in pharmaceutical film coatings. Over the past few decades, numerous studies have been carried out to illustrate zein’s potential for novel applications in the biomedical field. This paper reviews the present status of zein-based nanofibres, with emphasis on their fabrication and biomedical applications, particularly for drug delivery. Their benefits and limitations are also discussed to provide further insight into zein’s potential as a promising biomaterial.
Export Options
About this article
Cite this article as:
Zhang Yong, Cui Lili, Chen Yan, Zhang Heng, Zhong Jian, Sun Yanan, Shi Nianqiu, Li Chunlei and Kong Wei, Zein-Based Nanofibres for Drug Delivery: Classes and Current Applications, Current Pharmaceutical Design 2015; 21 (22) . https://dx.doi.org/10.2174/1381612821666150531170448
DOI https://dx.doi.org/10.2174/1381612821666150531170448 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ca2+ Signaling, Mitochondria and Cell Death
Current Molecular Medicine Treatment of Chronic Hepatitis B in Children
Recent Patents on Anti-Infective Drug Discovery Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Pilot Study to Evaluate the Effects of Oral N-Acetyl Cysteine on Inflammatory and Oxidative Stress Biomarkers in Rheumatoid Arthritis
Current Rheumatology Reviews Arachidonic Acid Cascade Enzyme Inhibition and Cancer
Current Enzyme Inhibition The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
Current Drug Discovery Technologies Editorial (Thematic Issue: Bioinformatics and Biotechnology)
Current Biotechnology Signal Transduction Pathway Regulated by Genistein and its Therapeutic Use
Current Signal Transduction Therapy MicroRNAs: Emerging Role in the Endogenous μ Opioid System
CNS & Neurological Disorders - Drug Targets Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions
Current Medicinal Chemistry Genetic Alleles Associated with SLE Susceptibility and Clinical Manifestations in Hispanic Patients from the Dominican Republic
Current Molecular Medicine The Role of Immune and Inflammatory Mechanisms in ALS
Current Molecular Medicine TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Design and Synthesis of IMR-23, an Oxime Derived from Nitroimidazole as an Immunomodulatory Molecule
Current Drug Delivery Establishment of Conditionally Immortalized Cell Lines with Specific Functions and its Application to Differential Gene Expression Analysis by DNA Microarray Technology
Current Pharmaceutical Analysis New Pathways for Reactive Oxygen Species Generation in Inflammation and Potential Novel Pharmacological Targets
Current Pharmaceutical Design Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry Development of Bruton’s Tyrosine Kinase Inhibitors for Rheumatoid Arthritis
Current Medicinal Chemistry Diet and Metabolic Syndrome: An Overview
Current Vascular Pharmacology